Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study

Charlotte Costentin 1, * Richard Layese 2 Valérie Bourcier 3 Carole Cagnot 4 Patrick Marcellin 5 Dominique Guyader 6 Stanislas Pol 7, 8, 9 Dominique Larrey 10, 11 Victor de Ledinghen 12 Denis Ouzan 13 Fabien Zoulim 14 Dominique Roulot 15 Albert Tran 16 Jean-Pierre Bronowicki 17 Jean-Pierre Zarski 18, 19 Ghassan Riachi 20 P. Calès 21 Jean-Marie Péron 22, 23 Laurent Alric 24 Marc Bourlière 25 Philippe Mathurin 26 Jean-Frédéric Blanc 27, 28 Armand Abergel 29, 30, 31, 32, 33 Lawrence Serfaty 34 Ariane Mallat 35, 36, 37 Jean-Didier Grangé 38 Pierre Attali 39 Yannick Bacq 40 Claire Wartelle Thong Dao 41 Dominique Thabut 42 Christophe Pilette Christine Silvain 43 Christos Christidis 44 Eric Nguyen-Khac 45 Brigitte Bernard-Chabert 46 David Zucman 47 Vincent Di Martino 48 Angela Sutton 3 Eric Letouzé 49 Sandrine Imbeaud 49 Jessica Zucman-Rossi 49, 50, 51, 52, 53 Etienne Audureau 54, 2 Françoise Roudot-Thoraval 54 Pierre Nahon 49
* Auteur correspondant
Abstract : Background & aims - Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis who developed HCC. Methods - We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France. Only 216 patients who developed HCC during the follow-up period were included in the analysis. Patients were considered to be compliant with surveillance guidelines if the time between their last surveillance image evaluation and diagnosis of HCC were fewer than 7 months and noncompliant if this time was 7 months or longer. Results - HCC was detected in 216 patients, at a median follow-up time of 59.7 months. Of these patients, 140 (80.5%) were Barcelona Clinic Liver Cancer stage 0/A, 135 (69.9%) received first-line curative treatment (15 underwent transplantation, 29 underwent resection, 89 received percutaneous ablation, and 2 received resection and percutaneous ablation), and 129 (60.0%) were compliant with surveillance guidelines. Seventy-nine of the patients with HCC died; 49 deaths were associated with tumor progression. After lead-time adjustment, overall survival (OS) time was longer in patients compliant with surveillance guidelines (median OS time, 53.2 months) than noncompliant patients (median OS time, 25.4 months) (P = .0107); this difference remained significant even when we changed lead time assumptions. In multivariate analysis adjusted for a propensity score, compliance with HCC surveillance guidelines was associated with low tumor burden, allocation of curative treatment, and increased OS time compared with noncompliance (hazard ratio for OS, 2.19; 95% confidence interval, 1.16-4.14; P = .0150). Conclusions - In an analysis of data from the ANRS CO12 CirVir cohort, we associated compliance with HCC surveillance guidelines (fewer than 7 months between image evaluations) with early diagnosis, allocation of curative treatment, and longer adjusted OS of patients with hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis and a diagnosis of HCC.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-02648451
Contributeur : Okina Université d'Angers <>
Soumis le : vendredi 29 mai 2020 - 09:36:03
Dernière modification le : vendredi 11 juin 2021 - 16:02:02

Identifiants

Citation

Charlotte Costentin, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, et al.. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, WB Saunders, 2018, 155 (2), pp.431-442.e10. ⟨10.1053/j.gastro.2018.04.027⟩. ⟨hal-02648451⟩

Partager

Métriques

Consultations de la notice

340